A silent outbreak due to Klebsiella pneumoniae that co-produced NDM-1 and OXA-48 carbapenemases, and infection control measures

Document Type: Original Article


1 Medical Microbiology Department, Inonu University Medical Faculty, Malatya, Turkey

2 Infections Disease Medical Microbiology Department, Inonu University Medical Faculty, Malatya, Turkey


Objective(s): Infections due to carbapenemase-producing Klebsiella pneumoniae are associated with high morbidity and mortality. In this study, we report a hospital outbreak due to co-producing OXA-48 and NDM-1 K. pneumoniae clone. The aim of the study is to investigate the clonal relationship of strains, risk factors of outbreak and infection control measures.
Materials and Methods: Once an outbreak was suspected at the end of December 2017 in our intensive care unit (ICU), carbapenem resistance K. pneumoniae identified in patients’ specimens. An outbreak analysis was begun to determine the risk factors and dissemination of the cases. A case-control study was conducted to determine the risk factors. To control the outbreak; tight contact prevention, good clean-up the medical devices and hospital environment, were done. Staff training programs such as hand hygiene, disinfection, wearing aprons, good cleaning were created. Carbapenem resistance genes determined by PCR. Clonal relationships of strains investigated by PFGE.
Results: We investigate 21 carbapenem-resistant K. pneumonia strains. Nine of them were found co-produced NDM-1 and OXA-48, 11 strains produced OXA-48, and one strain produced NDM-1. Seven strains of co-producing NDM-1 and OXA-48 were found clonally related with PFGE. We could not determine any risk factor except rectal colonization in the case-control study.
Conclusion: The interventions that successfully controlled this outbreak were hand hygiene, tight contact prevention, good clean-up of the hospital environment and medical devices. As a result, we believe that it would be beneficial to take infection control measures to prevent the spread of these strains to the community and hospital settings.


1. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 2014; 20: 821–830.
2. Couto RC, Carvalho EA, Pedrosa TM, Pedroso ER,  Neto MC,  Biscione FM.  A 10 year prospective surveillance of nosocomial infections in neonatal intensive care units. Am J Infect Control 2007;35:183–189.
3. Tao XB, Qian LH, Li Y, Wu Q, Ruan JJ, Cai DZ,  et al. Hospital-acquired infection rate in a tertiary care teaching hospital in China: a cross-sectional survey involving 2434 in patients. Int J Infect Dis 2014; 27:7-9.
4. Stefaniuk E, Suchocka U, Bosacka K, Hryniewicz W. Etiology and antibiotic susceptibility of bacterial pathogens responsible for community-acquired urinary tract infections in Poland. Eur J Clin Microbiol Infect Dis 2016; 35:1363-1369.
5. Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR 2009; 58:256–260.
6. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae.  Emerg Infect Dis 2011;17:1791–1798.
7. Albiger B, Glasner C, Struelens M, Grundmann H, Monnet D, the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 2015;20: 30062.
8. Barguigua A, El Otmani F, Lakbakbi EI Yaagoubi F, Talmi M, Zerouali K, Timinouni M. First report of a Klebsiella pneumoniae strain coproducing NDM-1, VIM-1 and OXA-48 carbapenemases isolated in Morocco. APMIS 2013;121:675-677.
9. Clinical and Laboratory Standards Institute. Performance Standard for Antimicrobial Susceptibility Testing. twenty-fifth Informational Supplement. Document M100-S25. CLSI, Wayne, PA, 2015.
10. Monteiro J, Widen RH, Pignatari AC, Kubasek C, Silbert S. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 2012: 67:906-909.
11. Ellington MJ, Kistler J, Livermore DM, Woodford N. Multiplex PCR for rapid detection of genes encoding acquired metallo-beta-lactamases. J Antimicrob Chemother 2007: 59:321-322.
12. Durmaz R, Otlu B, Koksal F, Hosoglu S, Ozturk R, Ersoy Y, et al. The optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 2009; 62:372-377.
13. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-950.
14. Alexander EL, Loutit J, Tumbarello M, Wunderink R, Felton T, Daikos G, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. Open Forum Infect Dis 2017;4:ofx063
15. Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Front Microbiol 2016:13;7:895.
16. Poirel L, Heritier C, TolunV, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
17. Aktas Z, Kayacan CB, Schneider I, Can B, Midilli K, Bauernfeind A. Carbapenem-hydrolyzing oxacillinase, OXA-48, persist in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy 2008;54: 101-106.
18. Carrer A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. Spread of OXA-48 positive carbapenem resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 2008;52: 2950-2954.
19. Us E, Tekeli A, Arikan Akan O, Dolapci I, Sahin F, Karahan ZC. Molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae strains isolated between 2004-2007 in Ankara University Hospital, Turkey. Mikrobiyol Bul 2010;44: 1-10.
20. Berrazeg M, Diene S, Medjahed L, Parola P, Drissi M, et al. New Delhi Metallo-beta-lactamase around the world:and review using Google Maps. Euro Surveillance 2014;19:1-14.
21. Poirel L, Yilmaz M, Istanbullu A, Arslan F, Mert A, Bernabeu S, et al. Spread of NDM-1-producing Enterobacteriaceae in a neonatal intensive care unit in Istanbul, Turkey. Antimicrob Agents Chemother 2014;58: 2929-2933.
22. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. CDC website. https://www.cdc.gov /drugresistance/threat-report-2013/pdf/ar-threats -2013-508.pdf. Accessed April 16, 2018.
23.  Lee CR, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology genetic context, treatment options, and detection methods. Front Microbiol 2016;7:895.
24. Kilic A, Baysallar M. The first Klebsiella pneumoniae isolate co-producing OXA-48 and NDM-1 in Turkey. Ann Lab Med 2015;35:382–383.
25. Guducuoglu H, Gursoy NC, Yakupogullari Y, Parlak M, Karasin G, Sunnetcioglu M, et al. Hospital Outbreak of a Colistin-Resistant, NDM-1- and OXA-48-Producing Klebsiella pneumoniae: High Mortality from Pandrug Resistance. Microb Drug Resist 2018;24:966-972.
26. Kola A, Piening B, PapeUF, Veltzke-Schlieker W, Kaase M, Geffers C, et al. An outbreak of carbapenem-resistant OXA-48-producing Klebsiella pneumoniae associated to duodenoscopy. Antimicrob Resist Infect Control 2015;4:8.
27. Pantel A, Richaud-Morel B, Cazaban M, Bouziges N, Sotto A, Lavigne JP. Environmental persistence of OXA-48-producing Klebsiella pneumoniae in a French intensive care unit. Am J Infect Control 2016;44:366–368.